Manage Medicinal Cannabis Funding with Confidence and Control
Without structured oversight, medicinal cannabis funding becomes an open-ended liability. Insurers risk approving multiple cannabis products at varying strengths and dosages indefinitely—potentially costing thousands of dollars per month with no clear exit strategy or measurable outcomes.
Our 12-week Medicinal Cannabis Management Program isn't optional—it's essential. If you're considering funding medicinal cannabis, this program provides the structure, accountability, and evidence you need to make defensible decisions and control costs.
Service Details
Our program simplifies the management of medicinal cannabis trials, offering comprehensive assessments throughout a 12-week period to ensure safe and effective use:
Our goal is to ensure medicinal cannabis is used safely and effectively, supporting recovery and informed decision-making.
Key Inclusions:
- Evaluating the appropriateness of medicinal cannabis as a treatment option
- Monitoring progress and treatment effectiveness
- Providing recommendations for ongoing or adjusted use based on trial outcomes
- Aligning medicinal cannabis use with recovery goals
Refer your claimant to our Medicinal Cannabis Management Program to confidently support their recovery journey.
The Risk of Unmanaged Cannabis Funding
Approving medicinal cannabis without oversight exposes insurers to:
- ✗ Escalating costs: Multiple products, increasing dosages, no end date
- ✗ Unclear outcomes: No baseline, no progress tracking, no measurable benefit
- ✗ Indefinite funding: No structured review points or exit criteria
- ✗ Product proliferation: Oils, flowers, capsules—all at premium prices
- ✗ Dosage creep: Strengths increasing without clinical justification
The financial impact: Without management, monthly costs can easily exceed $2,000-$3,000 per claimant with no certainty the treatment is working.
How Our Program Protects Your Investment
Our structured 12-week program provides three critical assessment points that give you control:
Pre-Initiation Report (Before funding approval)
Evaluates whether medicinal cannabis is clinically appropriate before you commit to funding, considering:
- Medical history and injury profile
- Previous treatment responses
- Realistic recovery goals
- Alternative treatment options
- Projected costs and duration
Outcome: Clear recommendation on whether to proceed—protecting you from inappropriate funding requests.
Mid-Way Report (6 weeks into trial)
Monitors progress and treatment effectiveness to catch issues early:
- Symptom improvement tracking
- Dosage appropriateness
- Side effects or complications
- Compliance with treatment plan
- Cost-benefit analysis
Outcome: Evidence-based decision to continue, modify, or discontinue—preventing waste on ineffective treatment.
Trial Conclusion Report (End of 12 weeks)
Provides final assessment with clear next steps:
- Overall treatment effectiveness
- Measurable outcomes achieved (or not)
- Recommendation: continue, taper, or cease
- Alternative treatment options if cannabis ineffective
- Long-term cost projections if continuation recommended
Outcome: Defensible decision on ongoing funding with clear rationale and exit criteria.
What's Included
Comprehensive oversight throughout the 12-week trial:
- Appropriateness evaluation – Is cannabis the right treatment for this injury?
- Progress monitoring – Is the treatment actually working?
- Cost control – Are product selections and dosages clinically justified?
- Evidence-based recommendations – Continue, modify, or cease with clear rationale
- Recovery goal alignment – Are we supporting return to work and function?
- Treating provider liaison – Communication with prescribing doctors when needed
Why This Service Is Non-Negotiable
If you're funding medicinal cannabis, you need this program. Here's why:
Without structured management:
- ✗ No baseline assessment of appropriateness
- ✗ No progress tracking or outcome measures
- ✗ No scheduled review points
- ✗ No clear criteria for continuation or cessation
- ✗ No cost controls or product justification
- ✗ Open-ended funding with no exit strategy
With our program:
- Clinical appropriateness confirmed before funding
- Structured progress monitoring at 6 and 12 weeks
- Evidence-based decisions at every stage
- Clear exit criteria and alternatives if ineffective
- Cost control through dosage and product oversight
- Defensible decision-making with expert recommendations
The Bottom Line
Medicinal cannabis without oversight is a financial and clinical risk you cannot afford.
Our program turns an open-ended liability into a structured, time-limited trial with clear decision points. You'll know within 12 weeks whether cannabis is delivering measurable benefit—or whether you should cease funding and pursue alternatives.
- Cost of program:
- Fixed fee for 12-week structured oversight
- Cost without program:
- $2,000-$3,000+ per month indefinitely
This isn't just good practice—it's essential risk management.
Ready to Refer?
If medicinal cannabis funding is being considered, refer to our Medicinal Cannabis Management Program immediately to:
- Protect against inappropriate or ineffective funding
- Establish clear treatment goals and success criteria
- Control costs through structured oversight
- Make defensible decisions with expert guidance
Don't fund cannabis without it.
Ask a Pharmacist!
Need expert advice? Contact us using the information above for an obligation-free discussion with one of our pharmacists. We’re here to provide the insights you need. If you prefer face-to-face, book a call!